ON THIS PAGE: You will find information about how many are diagnosed with this type of cancer each year. You will also learn some general information on surviving the disease. Remember, survival rates depend on several factors. To see other pages, use the menu on the side of your screen.
In general, a lacrimal gland tumor is rare. About half of lacrimal gland tumors are benign, and half are malignant. Malignant epithelial tumors of the lacrimal gland account for 2% of all orbital (eye socket) tumors. Adenoid cystic carcinoma (AdCC) is the most frequent epithelial orbital cancer, accounting for approximately 50% of malignant lacrimal gland tumors and 25% of all lacrimal gland tumors.
Survival rates depend on several factors, including the type and subtype of lacrimal gland tumor. The 5-year survival rate tells you what percent of people live at least 5 years after the cancer is found. Percent means how many out of 100. The 5-year survival rate of people with AdCC is estimated to be 50%, while the 15-year survival rate is estimated to be 25%. However, this and other survival rates depend on several factors, including the type of lacrimal gland tumor and stage of disease. Talk with your doctor about what to expect with your specific diagnosis.
It is important to remember that statistics on how many people survive this type of tumor are an estimate. The estimate comes from data based on people with a lacrimal gland tumor in the United States each year. So, your own risk may be different. Doctors cannot say for sure how long anyone will live with a lacrimal gland tumor. Also, experts measure the survival statistics every 5 years. This means that the estimate may not show the results of better diagnosis or treatment available for less than 5 years. Learn more about understanding statistics .
Source: DeAngelis, Dan, MD, FRCS, "Lacrimal Gland Tumors," http://reference.medscape.com/article/1210619-overview  (April 2015.)
The next section in this guide is Risk Factors . It explains what factors may increase the chance of developing this disease. Or, use the menu to choose another section to continue reading this guide.